secwatch.observer — SEC 8-K summary
======================================

Issuer:     Harmony Biosciences Holdings, Inc. (HRMY)
CIK:        0001802665
Form:       8-K
Filed at:   2025-11-04T23:59:59+00:00
Accession:  0001104659-25-105942
Event type: earnings
Sentiment:  positive
Materiality: 0.85
Item codes: 2.02, 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Harmony Biosciences Q3 revenue $239.5M (+29% YoY); raises FY2025 guidance to $845-865M
--------------------------------------------------------------------------------

- Q3 net revenue $239.5M (WAKIX), +29% YoY; GAAP EPS $0.87, adjusted EPS $1.08.
- Raised 2025 revenue guidance to $845-865M from $820-860M.
- Record quarterly patient adds ~500, total ~8,100 average narcolepsy patients.
- Cash & investments $778M; generated $106M cash flow in Q3.
- Pipeline: pitolisant HD IND filed; Phase 3 narcolepsy/IH starts Q4; orexin-2 agonist first subject Q4.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1802665/000110465925105942/0001104659-25-105942-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1802665/000110465925105942/hrmy-20251104x8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-25-105942

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer